Jan 24, 2023

Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement

Rehovot, Israel – January 24, 2023 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.

The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe’s leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendance from Biomica will be CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner.

Dr. Haber will take part in two industry panel discussions. These are entitled, “How to Turn Outstanding Microbiome Science into Effective & Efficient Products”, taking place on February 1, 2023, at 9:30am GMT and “Working with Microbiome Investors”, scheduled to take place later that day at 4:30pm GMT.

Dr. Meshner will be presenting on February 1, 2023, at 2:55pm, and the presentation is entitled, “Rationally Designed LBPs  From Computational & Pre-clinical Data to Clinical Studies.

Dr. Haber and Dr. Meshner will both be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.

About Biomica

Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.

 
Investor Relations

Kenny Green

Email: kenny.green@evogene.com

Tel: +1 212 378 8040

Public Relations

Lital Mamon

Email: lital.mamon@evogene.com

Tel: +972 8 931 2097

Back to all News

Highlighted News About Biomica

May 23, 2024

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]